Publications by authors named "T L Kindwall-Keller"
Article Synopsis
- - The study investigates the survival outcomes of patients receiving umbilical cord blood transplants (UCBT) across different racial and ethnic groups, focusing on Black, Latinx, White, and Asian patients, as previous research indicated disparities in survival rates.
- - A retrospective analysis of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) included 983 single and 1529 double UCBT recipients, measuring outcomes like overall survival (OS), disease-free survival, and transplant-related mortality over two years.
- - Results showed that while overall survival rates varied by race/ethnicity, with Latinx patients having significantly lower OS compared to Blacks, no significant differences were observed in child patients,
Article Synopsis
- There has been an increase in the number of hematopoietic cell transplants (HCT) and improvement in overall survival after these procedures for blood disorders, but the impact on racial/ethnic minorities is unclear.
- A study examined transplant rates and survival trends among non-Hispanic Whites, non-Hispanic African Americans, and Hispanics from 2009 to 2018, revealing that Hispanics and non-Hispanic African Americans experienced higher rates of transplant than non-Hispanic Whites.
- Despite overall improvements in survival rates across groups, non-Hispanic African Americans faced greater mortality risks after allogeneic transplants, indicating ongoing disparities that need to be addressed.
Article Synopsis
- Researchers created a prognostic model to predict outcomes for patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation by analyzing data from 623 patients in the U.S. (CIBMTR cohort) from 2000 to 2016.
- They identified key factors that influence mortality, assigning weighted scores based on age, donor matching, hemoglobin levels, and donor compatibility, which resulted in differing survival rates among low, intermediate, and high score groupings.
- The model was validated in a European cohort (EBMT), proving effective for predicting overall survival and transplant-related mortality, aiding clinicians in discussing transplantation prospects with myelofibrosis patients.
The field of hematopoietic cell transplantation and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant diseases. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice.
View Article and Find Full Text PDFObjective/background: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure.
Methods: Ganciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT.